CD52 (CAMPATH-1)Catalogue number: CD52-1
|Product Type||Primary Antibodies|
|Application||IHC, ELISA, WB, FC|
This antibody reacts with the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small peptide that is heavily glycosylated, and attached to the cell surface membrane via a GPI link. The apparent molecular mass of the antigen on SDS-PAGE is 25-29kD. CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.Humanised versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies.
1 litre of aqua demin. (0.5-1 μSi / cm) + 10 PBS tablets + 5 g BSA + 0.9 g Na azide
Concentration: 1 mg/ml
Working Concentration: (liquid conc.)
Positive Control: Tonsil
"These products are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals. ** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!"
1. Hale, G. et al. (1998). Improving the Outcome of Bone Marow Transplantation by using CD52 Monoclonal Antibodies to prevent graft-versus-host disease and graft rejection. Blood 92: 4581-4590
2. Salisbury, J.R. et al. (1994). Immunohistochemical analysis of CDw52 antigen expression in non-hodgkins lymphomas. J. Clin. Path. 47: 313 - 317.